What is HC Wainwright’s Estimate for Nkarta Q4 Earnings?

Nkarta, Inc. (NASDAQ:NKTX) – Equities researchers at HC Wainwright issued their Q4 2025 earnings estimates for Nkarta in a note issued to investors on Thursday, March 27th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.29) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s FY2029 earnings at ($0.99) EPS.

Nkarta (NASDAQ:NKTX) last issued its earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06.

A number of other research firms have also weighed in on NKTX. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Nkarta in a report on Thursday. Stifel Nicolaus reduced their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $14.86.

Nkarta Stock Performance

NASDAQ:NKTX opened at $2.00 on Friday. The business’s fifty day moving average is $1.99 and its 200 day moving average is $2.84. The firm has a market cap of $141.92 million, a price-to-earnings ratio of -1.06 and a beta of 0.90. Nkarta has a 52-week low of $1.31 and a 52-week high of $11.84.

Insider Activity at Nkarta

In related news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the transaction, the chief executive officer now owns 319,859 shares of the company’s stock, valued at $703,689.80. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nkarta

Hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. purchased a new position in shares of Nkarta during the 4th quarter valued at about $30,000. Sequoia Financial Advisors LLC purchased a new position in shares of Nkarta during the fourth quarter worth approximately $31,000. Erste Asset Management GmbH purchased a new position in shares of Nkarta during the third quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Nkarta in the 4th quarter worth approximately $37,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Nkarta in the 4th quarter valued at $45,000. Institutional investors own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.